top of page

InformAI Announces Commercial Launch of RadOncAI at RSNA 2026

Nov 23
2 min read

FOR IMMEDIATE RELEASE


FDA-cleared AI-enabled radiation dose planning software designed to accelerate clinical workflows, enhance plan quality and advance precision cancer care

HOUSTON, TX, and CHICAGO, IL — December 2, 2026 — InformAI, a Houston-based healthcare artificial intelligence company, announced the commercial launch of RadOncAI, its FDA-cleared, AI-enabled radiation therapy dose planning software. The product will be officially unveiled on Wednesday, December 2, at the Radiological Society of North America (RSNA) 2026 Annual Meeting at McCormick Place in Chicago, in booth 5546 at the product launch at 11:20am.

RadOncAI represents a significant advancement in the application of artificial intelligence to radiation oncology, initially addressing the complex challenges associated with head and neck cancer radiation dose planning. The software is designed to generate patient-specific radiation dose plans in minutes rather than hours, helping clinical teams streamline workflows, improve planning consistency and optimize the use of healthcare resources.

Traditional radiation treatment planning is a time-intensive, iterative process that requires highly specialized clinical expertise. As cancer incidence increases and oncology practices face growing workforce constraints, the need for innovative technologies that support clinical productivity without compromising quality has become increasingly important.

RadOncAI is designed to address these challenges through advanced deep learning technology that supports:

  • Rapid generation of patient-specific radiation dose plans.

  • Greater consistency and standardization of dose planning.

  • Optimization of radiation dose distributions and sparing of healthy tissue.

  • Reduced planning iterations and manual workload.

  • Increased operational efficiency and clinical capacity.

  • Integration into established radiation oncology workflows.

Developed in collaboration with UT Southwestern Medical Center and supported by funding from the Cancer Prevention and Research Institute of Texas (CPRIT), RadOncAI reflects years of research, clinical development and validation. The software recently received U.S. Food and Drug Administration (FDA) 510(k) clearance (K253050) for its head and neck cancer application.


“The commercial launch of RadOncAI marks an important milestone for InformAI and our commitment to advancing cancer care through artificial intelligence. Our objective is to empower radiation oncology teams with technology that accelerates complex clinical workflows, supports consistent, high-quality dose planning and ultimately expands access to advanced cancer care,” said Jim Havelka, Founder and CEO of InformAI.

The launch also establishes the foundation for InformAI’s broader radiation oncology platform strategy, with ongoing research and development focused on expanding its technology to additional anatomical regions and cancer indications.

Experience RadOncAI at RSNA 2026

InformAI invites radiation oncologists, medical physicists, medical dosimetrists, healthcare executives, investors and industry partners to attend its official product launch and experience live demonstrations of RadOncAI.

  • Date: Wednesday, December 2, 2026

  • Time: 11:20 am

  • Location: McCormick Place, Chicago, Illinois

  • InformAI Booth: 5546 in the AI Showcase

  • Website: www.informai.com

About InformAI

InformAI is a healthcare artificial intelligence company headquartered in Houston, Texas, within the Texas Medical Center ecosystem. The company develops purpose-built, AI-enabled clinical solutions designed to improve healthcare delivery, enhance clinical decision-making and unlock significant economic value. InformAI’s technology portfolio spans radiation oncology, medical imaging and organ transplantation, with a focus on addressing complex clinical challenges through advanced artificial intelligence.

For more information, visit www.informai.com.

Media Contact

Jackie Coleman InformAI jcoleman@informai.com 832 754 5350


 
 
bottom of page